NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis

Praxis Precision Medicines, Inc. (PRAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PRAX

$256.47

−$8.02 (−3.03%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRAX with… →

PRAX Key Statistics

As of Oct 21, 2026
Trading
Open
$266.03
Previous Close
$264.49
Day's Range
256.05–272.00
52-Week Range
154.45–392.70
Volume
444.37K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.81
Valuation
Market Cap
$7.16B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.95
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$303.27M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.92M
1-Year Return
+34.97%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
454.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PRAX closed at $256.47, +34.97% over 1 year.

Praxis Precision Medicines, Inc. (PRAX) has a market capitalization of $7.16B.

In fiscal 2025, PRAX reported revenue of $0.00.

PRAX Stock Return by Calendar Year

Praxis Precision Medicines, Inc. (PRAX) return since Oct 2020: what $10,000 became

1 year
$10,000 $13,497
+34.97%
5 years
$10,000 $7,872
−21.28%
Since Oct 2020
$10,000 $6,150
−38.50%

If you had invested $10,000 in Praxis Precision Medicines, Inc. (PRAX) at the close on October 16, 2020, the earliest close on record here, it would have been worth $6,150 at the close on October 21, 2026: −38.50% in total, −7.77% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.98%
2025+282.98%
2024+245.42%
2023−37.59%
2022−87.92%
2021−64.19%
2020 (partial year)+97.91%

As of October 21, 2026.

PRAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$303.27M—
2024$8.55M−$182.82M−2,137.5%
2023$2.45M−$123.28M−5,037.9%
2022$0.00−$214.03M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$326.20M−$303.27M—
2024$8.55M—−$200.17M−$182.82M−2,137.5%
2023$2.45M—−$126.37M−$123.28M−5,037.9%
2022$0.00—−$214.99M−$214.03M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Praxis Precision Medicines, Inc. (PRAX) carries a market capitalisation of $7.16B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 168.

The most recent close on file for PRAX is $256.47, dated October 21, 2026. That is −$8.02 (−3.03%) against the previous close. Over the past 52 weeks the price has ranged from $154.45 to $392.70. The latest close sits 66.05% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. That is −100.00% against the prior fiscal year, when revenue was $8.55M. The same year closed with a net loss of $303.27M. Trailing earnings per share are −12.95.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +34.97%. Across 5 years the annualized return works out at −4.67%. The reported beta is 2.81. Daily returns over the trailing 6 years annualize to a volatility of 121.14%.

Growth & Income

The record shows no dividend for PRAX.

2026 is still running; the total return is −12.98% year to date. Across the complete calendar years on file, 2025 returned +282.98% and 2022 returned −87.92%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Praxis Precision Medicines, Inc. (PRAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Praxis Precision Medicines, Inc. PRAX $7.16B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Praxis Precision Medicines, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Visit website →